Immunotherapy in MSI-H Colorectal Cancer: A New Era
Immunotherapy for Colorectal Cancer: A shifting Landscape
Table of Contents
For years, patients diagnosed with colorectal cancer received a dishearteningly consistent answer to the question, “Could immunotherapy be an option for me?” The response was a firm “no.” However,that’s changing. A growing body of research indicates immunotherapy, once largely ineffective against this type of cancer, is now showing promise for a subset of patients.this shift represents a meaningful turning point in colorectal cancer treatment,fueled by 15 years of advancements in oncology and validated by groundbreaking clinical trials.
The revolution in cancer treatment over the past decade and a half has been remarkable. Immunotherapy, which harnesses the power of the body’s own immune system to fight cancer, has dramatically altered the treatment paradigm for many cancers.This progress has been recognized with three Nobel Prizes, highlighting its profound impact. In contrast, chemotherapy, while still a mainstay of treatment, often carries a more negative public perception due to its well-known side effects.
Understanding the Shift
historically, colorectal cancers were considered “immunologically cold,” meaning they didn’t provoke a strong immune response. This made them resistant to immunotherapy drugs designed to unleash the immune system. However, researchers have discovered that a significant minority of colorectal cancers – especially those with specific genetic mutations – do harbor immune cells and are susceptible to immunotherapy.
The key lies in identifying these patients. Specifically, tumors with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) are more likely to respond to immunotherapy. These defects lead to a higher mutation burden, making the cancer cells more recognizable to the immune system.
| Biomarker | Description | Immunotherapy Response |
|---|---|---|
| MSI-H (High Microsatellite Instability) | Indicates defects in DNA mismatch repair, leading to increased mutations. | Generally good response to immunotherapy. |
| dMMR (Mismatch Repair Deficiency) | Similar to MSI-H, reflects impaired DNA repair mechanisms. | Generally good response to immunotherapy. |
| pMMR (Proficient Mismatch Repair) | Indicates functional DNA mismatch repair. | Typically poor response to single-agent immunotherapy. |
Current Immunotherapy Approaches
The most common type of immunotherapy used in colorectal cancer is checkpoint inhibition. These drugs, such as pembrolizumab and nivolumab, block proteins that prevent the immune system from attacking cancer cells. they essentially “release the brakes” on the immune response.
While single-agent immunotherapy has shown benefit in MSI-H/dMMR tumors, researchers are also exploring combinations with chemotherapy, targeted therapies, and other immunotherapies to improve outcomes in patients with more common, pMMR tumors.
What does This Mean for Patients?
If you’ve been diagnosed with colorectal cancer, it’s essential to discuss immunotherapy with your oncologist.Specifically, ask about biomarker testing for MSI-H and dMMR.